PurMinds NeuroPharma News Releases

PurMinds NeuroPharma Announces Its First Botanical Psilocybin Delivery to Bluestem API Inc.

Tue, 18 Jun 2024 08:30:00 -0400

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - June 18, 2024) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuro-medicine development company focused on advancing novel therapeutics for neurological and neurodegenerative disorders, today announced that it has signed the first Controlled Substances Supply Agreement with Bluestem API Inc ("Bluestem") to produce and supply botanical psilocybin from its Ontario based neurolab and production facility that holds a Dealer's...

PurMinds NeuroPharma Announces PUR501 as Lead Candidate Novel Non-Hallucinogenic Neuroplastogen

Thu, 30 May 2024 08:30:00 -0400

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 30, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced its selection of...

PurMinds NeuroPharma Appoints Vanessa Williamson as Chief Business Officer

Thu, 23 May 2024 08:30:00 -0400

Seasoned Executive to Drive Strategic Partnerships and Business Development for Pioneering Neuroscience Company Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 23, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced that Vanessa Williamson has...

PurMinds Chief Scientific Officer to Speak at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Tue, 21 May 2024 08:30:00 -0400

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 21, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced that Professor Alan P. Kozikowski, Ph.D., Chief Scientific Officer, will be presenting at the 4th Annual Psychedelic Therapeutics and Drug...

PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit

Tue, 06 Feb 2024 08:30:00 -0500

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds™" or the "Company"), a clinical-stage neuroscience company dedicated to the development of innovative therapies for neurological and neurodegenerative disorders, is thrilled to announce its selection as one of the prestigious presenters at the upcoming 2024 OBIO® Investment Summit. The OBIO® Investment Summit, renowned for its focus on fostering growth and innovation in the...

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Thu, 14 Dec 2023 08:30:00 -0500

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - December 14, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that its management team, including Chief Executive Officer Janet Qi and Chief Scientific Officer Dr. Alan Kozikowski, will be...

PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Wed, 29 Nov 2023 08:49:00 -0500

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 29, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced that Dr. Amy Reichelt, Ph.D., the company's Chief Innovation Officer, will be speaking at the Analytical Cannabis Educational Webinar...

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Thu, 09 Nov 2023 08:30:00 -0500

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 9, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the role of Chief Scientific Officer...

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Tue, 07 Nov 2023 08:30:00 -0500

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 7, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that under its Health Canada Dealer's License for Controlled Drugs and Substances ("Dealer's License"), it has tripled its...

PurMinds(TM) NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply

Wed, 11 Oct 2023 09:04:00 -0400

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 11, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that under its Health Canada Schedule 1 Dealer's License for Controlled Drugs and Substances ("Dealer's License"), it has been...